Please login to the form below

Not currently logged in
Email:
Password:

Former Glaxo CEO Ernest Mario to chair Chimerix

Pharma veteran has previously also served as CEO of Alza and Reliant

Chimerix Ernest MarioChimerix has appointed pharma veteran and former CEO of Glaxo Holdings Dr Ernest Mario as the company's new chairman.

Mario (pictured right) was CEO of Glaxo from 1989 to 1993, ahead of its subsequent merger with Wellcome in 1995 and then SmithKline Beecham in 2000 to eventually form GlaxoSmithKline (GSK).

Following his departure from Glaxo, Dr Mario served as chairman and CEO of Alza from 1993 until its acquisition by Johnson & Johnson (J&J) in 2011.

He then held the role of chairman and CEO of Reliant Pharmaceutical from 2003 until its acquisition by GSK in 2007.

Dr Mario currently serves as chairman and CEO of US-based biopharma Capnia.

"Ernie brings to Chimerix a unique breadth and depth of experiences across large and early stage pharmaceutical firms,” said Kenneth Moch, president and CEO of Chimerix.

“His knowledge will be invaluable as we seek to progress our lead compound, CMX001, through phase III clinical development and commercial launch."

Dr Mario replaces Dr James Niedel, who will remain as a member of the board at Chimerix.

26th February 2013

From: Sales

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Viseven

Viseven is a Global MarTech Services Provider for Pharma and Life Sciences Industries...

Latest intelligence

Flu
Influenza – the risk to vulnerable populations
Why we can't get complacent about flu vaccination...
dementia
Alzheimer’s Research UK highlights socio-economic inequalities in dementia risk
The charity aims to improve the number of women participating in dementia research and grow awareness of dementia risk factors...
Data security
Concerns about data security are building a strong case for clinical mobility in EMEA
Electronic medical records have transformed the storage of sensitive information but how can the healthcare sector continue to protect patient and staff data?...